Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
| ▸ | HNF4A | P41235 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862546 | 0.84 | NOTUM (0.50) | L3MBTL1ALDH1A1POLBMAPK1GABRA5 | |
| SCHEMBL440238 | 0.84 | NOTUM (0.50) | L3MBTL1ALDH1A1POLBMAPK1GABRA5 | |
| SCHEMBL2716927 | 0.83 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL2716074 | 0.83 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL2715270 | 0.82 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL2715676 | 0.82 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL14762361 | 0.82 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL2714025 | 0.82 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL2716993 | 0.81 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA | |
| SCHEMBL2715678 | 0.81 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1MRGPRX4POLBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
| CN-108299400-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-06 | — | — | US | disclosed |
| EP-3345902-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart NeuroScience (Cayman) Ltd (KY) | 2018-07-11 | — | — | EP | disclosed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-3074400-B1 | OCTAHYDRO-CYCLOBUTA [1,2-C;3,4-C']DIPYRROLE DERIVATIVES AS AUTOTAXIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8227491-B2 | 5-(3,4-dichloro-phenyl)-N-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2475645-A1 | 5- (3, 4-DICHLORO-PHENYL) -N- (2-HYDROXY-CYCLOHEXYL) -6- (2,2, 2-TRIFLUORO-ETHOXY) -NICO TINAMIDE AND SALTS THEREOF AS HDL CHOLESTEROL RAISING AGENTS | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011029827-A1 | 5- (3, 4-DICHLORO-PHENYL) -N- (2-HYDROXY-CYCLOHEXYL) -6- (2,2, 2-TRIFLUORO-ETHOXY) -NICO TINAMIDE AND SALTS THEREOF AS HDL CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029827-A1 | 5- (3, 4-DICHLORO-PHENYL) -N- (2-HYDROXY-CYCLOHEXYL) -6- (2,2, 2-TRIFLUORO-ETHOXY) -NICO TINAMIDE AND SALTS THEREOF AS HDL CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065759-A1 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY)-NICOTINAMIDE AND SALTS THEREOF | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065759-A1 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY)-NICOTINAMIDE AND SALTS THEREOF | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065759-A1 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY)-NICOTINAMIDE AND SALTS THEREOF | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | L3MBTL1 4719/4885ALDH1A1 1288/4885MRGPRX4 162/4885 |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | L3MBTL1 4719/4885ALDH1A1 1288/4885MRGPRX4 162/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | L3MBTL1 4719/4885ALDH1A1 1288/4885MRGPRX4 162/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | L3MBTL1 4723/4885ALDH1A1 1356/4885MRGPRX4 163/4885 |
| US-20110065759-A1 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY)-NICOTINAMIDE AND SALTS THEREOF | NNT, PCSK9, NADK | L3MBTL1 4141/4885ALDH1A1 760/4885MRGPRX4 4510/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | L3MBTL1 586/4885ALDH1A1 569/4885MRGPRX4 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.